Kymera Investor Presentation Deck

% Change from C1D1 Predose (Mean ± SEM) 400 300 200 400 300 200 200 100 50 0- -25 STAT3 Degradation Elicits IFN-y Response Gene Signature in Blood and Tumor Blood CXCL9 mRNA 2 3 4 5 6 7 8 CXCL10 mRNA KYMERA 2 3 4 5 6 STAT1 mRNA 1 2 3 4 5 ● 6 7 7 9 10 11 12 8 9 10 11 12 A Time Course of Transcriptional Induction of Select IFNy Stimulated Genes Post KT-333 Infusion 8 9 10 11 12 A 29 30 31 32 33 34 35 36 37 29 30 31 32 33 34 35 36 37 29 30 31 32 33 34 35 36 37 A Days in Study % Change from C1D1 Predose (Mean ± SEM) 300- ©2023 KYMERA THERAPEUTICS, INC. 200 100 50 0 -25 100 50- 0- -25 -50 200 100 50 0 -25 -50 -75 IDO1 mRNA 2 3 LAG3 mRNA 1 4 5 6 7 2 3 4 5 6 PD-L1 mRNA 2 3 4 5 6 7 7 8 9 10 11 12 8 9 10 11 12 29 30 31 32 33 34 35 36 37 8 A 29 30 31 32 33 34 35 36 37 9 10 11 12 Days in Study 29 30 31 32 33 34 35 36 37 DL2 DL3 DL4 DL5 A KT-333 IV + Tumor Change from Screening (%) 300 200 100 0 -50 Enrichment Score 0.4 11 0.2 0.0 KT-333 Leads to Induction of IFNY Pathway Response and Downregulation of SOCS3 in a CTCL Tumor CXCL10 JO Post KT-333 Treatment (C1D9) CXCL9 STAT1 10000 IFN y Response Pathway 20000 IDO1 Rank LAG3 Summary: Induction of IFN-y signature in tumor by KT-333 consistent with preclinical findings where effect in syngeneic solid tumor model associated with enhanced response to anti-PD-1 30000 SOCS3 40000 PAGE 31

View entire presentation